RNA m6A甲基化与肝细胞癌的相关性及对肝癌患者预后作用的Meta分析*

doi:10.3969/j.issn.1672-5069.2025.02.024

实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (2): 254-257.doi: 10.3969/j.issn.1672-5069.2025.02.024

RNA m6A甲基化与肝细胞癌的相关性及对肝癌患者预后作用的Meta分析^*

何培, 冯磊, 曹向红, 王佳, 彭传梅, 孔凡斌, 陶春晖, 张振华

650000 昆明市昆明医科大学附属延安医院检验科(何培,冯磊,曹向红,王佳,彭传梅,孔凡斌);安徽医科大学第二附属医院感染病科(陶春晖,张振华)

收稿日期:2024-04-17 出版日期:2025-03-10 发布日期:2025-03-11
通讯作者: 张振华,E-mail:zzh1974cn@163.com
作者简介:何培,女,34岁,医学博士,主治医师。E-mail:hepei839872218@126.com
基金资助:
^*国家自然科学基金地区科学基金资助项目(编号:82160402);云南省医学领军人才培养计划项目(编号:L-2019022);云南省科技厅-昆明医科大学应用基础研究联合专项重点项目(编号:202301AY070001-024);云南省教育厅-青年人才基础研究计划项目(编号:2024J0276)

A Meta analysis of correlation of RNA m6A methylation to prognosis of patients with hepatocellular carcinoma

He Pei, Feng Lei, Cao Xianghong, et al

Clinical Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650000, Yunan Province, China

Received:2024-04-17 Online:2025-03-10 Published:2025-03-11

摘要/Abstract

摘要： 目的许多研究探讨了RNA m6A 甲基化修饰器在肝细胞癌(HCC)中的作用,但目前的研究结果存在争议。因此,我们进行了荟萃分析以全面研究RNA m6A 甲基化与HCC风险的关系以及对生存预后的影响。方法应用计算机检索2024年3月以前的中文数据库(知网和万方)、外文数据库(Pubmed、OVID、EBSCO、web of science)所收录的相关的中外文文献,收集有关RNA m6A甲基化与HCC发展、预后的关联文献病例对照研究。依照纽卡斯尔-渥太华量表(NOS)对纳入的中外文的文献行质量评价。应用RevMan 5.3软件行统计学分析。结果纳入文献11篇,累计病例3586例,其中HCC组1071例,癌旁组织组2515例;HCC组织m6A甲基化阳性率为61.7%,显著高于肝组织【38.5%,OR=4.77,95% CI(2.58～8.82),P<0.00001】;HCC组织FTO、METTL3、YTHDF1和ALKBH5表达量与患者预后密切相关【HR=1.3,95%CI(1.17～1.44),P<0.00001】。结论 RNA m6A 高甲基化与HCC发生密切相关,且HCC组织m6A甲基化修饰器FTO、METTL3、YTHDF1和ALKBH5高表达者预后差。

关键词: 肝细胞癌, m6A RNA, 甲基化, 预后, 荟萃分析

Abstract: Objective Many studies have explored the role of RNA m6A methylation modifiers in hepatocellular carcinoma (HCC), but the current results are controversial. Therefore, we conducted a meta-analysis to comprehensively study the relationship between RNA m6A methylation and the risk of liver cancer and the prognosis of patients with HCC. Methods We searched Chinese and English literatures database before March 2024, including Chinese databases Wanfang and CNKI, and English databases, Pubmed, OVID, EBSCO and web of science. Related literatures as case-control studies, on RNA m6A methylation and the development and prognosis of patients with HCC were retrieved. The quality of the literature was evaluated according to the Newcastle- Ottawa scale (NOS) scoring system. Based on inclusion and exclusion criteria, the literature was screened and the data was extracted, and the RevMan5.3 software was applied for statistical analysis. Results A total of 11 articles were found, including 3586 patients with HCC (1071 HCC tissues and 2515 adjacent liver tissue); the positive rate of m6A methylation in HCC tissues was 61.7%, significantly higher than 38.5% [OR= 4.77, 95% CI (2.58-8.82), P<0.00001] in liver tissues; hepatic expressions of FTO, METTL3, YTHDF1 and ALKBH5 were positively correlated to poor prognosis of patients with HCC [HR=1.3, 95%CI(1.17-1.44),P<0.00001]. Conclusion RNA m6A hypermethylation is closely related to the occurrence of liver cancer, and the expressions of m6A methylation modifiers, such as FTO, METTL3,YTHDF1 and ALKBH5 genes in liver cancer tissues are closely related to the poor prognosis of patients with HCC.

Key words: Hepatoma, m6A RNA, Methylation, Prognosis, Meta-analysis

何培, 冯磊, 曹向红, 王佳, 彭传梅, 孔凡斌, 陶春晖, 张振华. RNA m6A甲基化与肝细胞癌的相关性及对肝癌患者预后作用的Meta分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 254-257.

He Pei, Feng Lei, Cao Xianghong, et al. A Meta analysis of correlation of RNA m6A methylation to prognosis of patients with hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2025, 28(2): 254-257.

参考文献

[1] Craig AJ, von Felden J, Garcia-Lezana T, et al. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2020, 17(3):139-152.
[2] Toh MR, Wong EYT, Wong SH, et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology, 2023, 164(5):766-782.
[3] Johnson P, Zhou Q, Dao DY, et al. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2022, 19(10):670-681.
[4] Hu J, Cai J, Park SJ, et al. N6-Methyladenosine mRNA methylation is important for salt stress tolerance in Arabidopsis. Plant J, 2021, 106(6):1759-1775.
[5] Du LQ, Wang XJ, Sun YQ. N6-methyl-adenosine (m6A) in RNA modifications and gametog -enesis. J Int Reprod Health/Fam Plan, 2015, 34(5):410-414.
[6] Li HB, Tong J, Zhu S, et al. m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature, 2017, 548(7667):338-342.
[7] Wang T, Kong S, Tao M, et al. The potential role of RNA N6-methyladenosine in Cancer progression. Mol Cancer, 2020, 19(1):88.
[8] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9):603-605.
[9] Hu BB, Wang XY, Gu XY, et al. N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers: roles, mechanisms, and applications. Mol Cancer, 2019, 18(1):178.
[10] Jiang X, Liu B, Nie Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther, 2021, 6(1):74.
[11] Yi D, Wang R, Shi X, et al. METTL14 promotes the migration and invasion of breast cancer cells by modulating N6methyladenosine and hsamiR146a5p expression. Oncol Rep, 2020, 43(5):1375-1386.
[12] Zhang B, Wu Q, Li B, et al. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer, 2020, 19(1):53.
[13] Zhang QJ, Luan JC, Song LB, et al. m6A RNA methylation regulators correlate with malignant progression and have potential predictive values in clear cell renal cell carcinoma. Exp Cell Res, 2020, 392(1):112015.
[14] Sui X, Hu Y, Ren C, et al. METTL3-mediated m6A is required for murine oocyte maturation and maternal-to-zygotic transition. Cell Cycle, 2020, 19(4):391-404.
[15] Zhao TX, Wang JK, Shen LJ, et al. Increased m6A RNA modification is related to the inhibition of the Nrf2-mediated antioxidant response in di-(2-ethylhexyl) phthalate-induced prepubertal testicular injury. Environ Pollut, 2020, 259:113911.
[16] Ianniello Z, Paiardini A, Fatica A. N6-methyladenosine (m6A): A promising new molecular target in acute myeloid leukemia. Front Oncol, 2019, 9:251.
[17] Shen C, Sheng Y, Zhu AC, et al. RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia. Cell Stem Cell, 2020, 27(1):64-80,e9.
[18] Du J, Hou K, Mi S, et al. Malignant evaluation and clinical prognostic values of m6A RNA methylation regulators in glioblastoma. Front Oncol, 2020, 10:208.
[19] Wang X, Fu X, Zhang J, et al. Identification and validation of m6A RNA methylation regulators with clinical prognostic value in Papillary thyroid cancer. Cancer Cell Int, 2020, 20:203.
[20] Roignant JY, Soller M. m6A in mRNA: An ancient mechanism for fine-tuning gene expression. Trends Genet, 2017, 33(6):380-390.

RNA m6A甲基化与肝细胞癌的相关性及对肝癌患者预后作用的Meta分析^*

A Meta analysis of correlation of RNA m6A methylation to prognosis of patients with hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李全维, 高明慧, 寇卜心, 柴梦音, 霍云飞, 豆双双, 庞丽君, 石英, 刘晓霓. p65通过调控脂代谢影响HepG2细胞增殖研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 173-177.
[2]	郭建晖, 周永兵, 何钦. 慢加急性乙型肝炎肝衰竭患者血清sST2、TLR4、suPAR和Beclin1水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(2): 230-233.
[3]	李士伟, 李家国, 诸靖, 张颖洁. 乙型肝炎相关慢加急性肝衰竭患者血清ANGPTL2、sVAP-1和HMGB1水平变化及其预测预后的价值研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 234-237.
[4]	严隽瑶, 尹国文, 徐清宇, 尤然, 秦锦霞. 阿替利珠单抗联合射频消融术治疗不可切除的肝细胞癌患者临床疗效和安全性研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 262-265.
[5]	周敏, 李涛, 王波玲. 超声造影联合血清PIVKA-Ⅱ水平评估TACE治疗的老年肝细胞癌患者完全缓解价值分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 270-273.
[6]	钟新梅, 闫莉莉, 张冬梅. 细菌性肝脓肿患者临床特征与病原菌分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 286-289.
[7]	封顺, 赵磊, 张丽娟. 慢加急性肝衰竭患者血清人β防御素-1、高尔基体蛋白73和白介素-33水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(1): 80-83.
[8]	孙敏, 张倩, 徐刚, 王加林, 何振文. ACLF患者肺部感染发生率及预测因素分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 84-87.
[9]	许文慧, 许箐贇, 李彬彬, 潘超. 间接测热法与公式法测定失代偿期乙型肝炎肝硬化患者静息能量消耗临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(1): 116-119.
[10]	牛日雨, 王益杰, 王欣, 李成忠. 基于癌症基因组图谱数据库双硫死亡相关LncRNA构建肝细胞癌预后模型及其效能分析[J]. 实用肝脏病杂志, 2025, 28(1): 128-131.
[11]	伏林, 张龄尹, 魏倩. MRI在脂肪肝背景下对局灶性结节性病变定性诊断价值分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 140-143.
[12]	杨爽, 高学松, 段雪飞. 难治性原发性胆汁性胆管炎研究进展^*[J]. 实用肝脏病杂志, 2025, 28(1): 156-159.
[13]	张少博, 张树庚, 刘连新. 免疫治疗肝细胞癌肝移植患者现状和前景展望^*[J]. 实用肝脏病杂志, 2024, 27(6): 801-803.
[14]	郑浩, 张树庚, 王嘉倍, 郭亚飞. 肝移植术治疗肝细胞癌患者肿瘤复发再治疗策略^*[J]. 实用肝脏病杂志, 2024, 27(6): 804-807.
[15]	朱泽斌, 张树庚, 刘连新. 靶向和免疫治疗原发性肝癌:肝移植术前降期治疗应用进展^*[J]. 实用肝脏病杂志, 2024, 27(6): 808-811.